Phase 1 Pancreatic Cancer Trial, Recruiting (NCT06917079)

Phase 1 Pancreatic Cancer Trial, Recruiting NCT06917079 Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Condition: Pancreatic Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06917079 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pancreatic Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a specific type of advanced cancer (non-small cell lung cancer, pancreatic cancer, colorectal cancer, or another solid tumor) that has spread or cannot be surgically removed, and your tumor has been confirmed by a lab test to have a specific gene change called a KRAS G12A, G12C, G12D, G12S, or G12V mutation
Your cancer can be measured on scans using a standard measurement system called RECIST v1.1
You are generally able to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required)
Doctors expect your life expectancy to be more than 24 weeks (about 6 months)
Your liver, kidneys, blood, and other organs are functioning well enough as shown by lab tests (confirm with trial site for specific levels required)

Who may not be able to join:

You have been diagnosed with another cancer within the last 2 years (confirm with trial site for specific exceptions listed in the protocol)
You have cancer that has spread to the brain and has not yet been treated

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (650) 405-4770

Australian sites

Peter MacCallum Cancer Centre, Melbourne, Victoria
03-8559-5000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06917079

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase: Phase 1

Status: Recruiting

Condition: Pancreatic Cancer

Trial contact: (650) 405-4770

More information: https://clinicaltrials.gov/study/NCT06917079

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a specific type of advanced cancer (non-small cell lung cancer, pancreatic cancer, colorectal cancer, or another solid tumor) that has spread or cannot be surgically removed, and your tumor has been confirmed by a lab test to have a specific gene change called a KRAS G12A, G12C, G12D, G12S, or G12V mutation
Your cancer can be measured on scans using a standard measurement system called RECIST v1.1
You are generally able to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required)
Doctors expect your life expectancy to be more than 24 weeks (about 6 months)
Your liver, kidneys, blood, and other organs are functioning well enough as shown by lab tests (confirm with trial site for specific levels required)

Who may not be able to join:

You have been diagnosed with another cancer within the last 2 years (confirm with trial site for specific exceptions listed in the protocol)
You have cancer that has spread to the brain and has not yet been treated

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Registry

ClinicalTrials.gov

Start date

31 March 2025

Est. completion

1 August 2027

Where this trial is recruiting

🇦🇺 Australia 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Incidence and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs); Determine recommended dose of BBO-11818 in combination with pembrolizumab ± cis/carboplatin + pemetrexed, cetuximab ± mFOLFOX6, BBO-10203 + mFOLFOX6, BBO-10203 + cetuximab, cetuximab, mFOLFIRINOX, gemcitabine + nab-paclitaxel, or BBO-10203

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov